Plain-English answer
Sources are not interchangeable. A page about FDA authorization needs FDA material. A page about Medicare payment needs CMS coding, coverage, and payment material. A page about China insurance needs NHSA or local payer material. A page about disease burden needs epidemiology and public-health data. A page about hospital adoption needs procurement, workflow, payer, and implementation evidence.
Why source fit matters
U.S.-China healthcare analysis becomes weak when it treats all citations as equal. A peer-reviewed article can be excellent evidence for a clinical question and still be insufficient for a reimbursement question. A regulator can explain market authorization but not guarantee coverage, payment, or hospital purchasing. A national statistic can describe system scale while concealing local variation in access, implementation, and price.
The site therefore uses source families. Official agencies explain authority and rules. Statistical agencies and international datasets show scale and trends. Regulators explain approval pathways and compliance obligations. Payers and procurement documents show how products or services move from permission into access. Peer-reviewed literature explains clinical, epidemiologic, health-services, and economic evidence. Field sources help interpret what actually happens in hospitals, provinces, payer review, tenders, partner selection, and sales execution.
Source map
| Question | Best source family | What it can answer |
|---|---|---|
| Who has authority? | Laws, agency rules, official guidance. | Mandate, jurisdiction, pathway, formal requirement. |
| How large is the system? | NBS, NHC, CMS, OECD, WHO, CDC, official yearbooks. | Population, facilities, spending, workforce, disease indicators. |
| Can a product be marketed? | FDA, NMPA, product databases, review guidance. | Regulatory class, filing route, evidence expectations, postmarket duties. |
| Will anyone pay? | CMS, NHSA, local reimbursement, payer policies, coding materials. | Coding, coverage, payment, formulary, benefit, patient cost exposure. |
| Will providers adopt? | Procurement records, hospital policy, KOL input, workflow evidence. | Purchasing gate, service model, training burden, economics, clinical fit. |
Examples
CMS explicitly organizes information for medical technology companies around coding, coverage, and payment. That is a useful model because these are related but distinct steps. FDA's device materials similarly show that clearance, approval, establishment registration, listing, labeling, quality systems, clinical evidence, and postmarket obligations are separate questions. In China, a basic insurance claim should not be sourced only to a broad health-system article when NHSA statistics or local policy material are available.
For data quality, WHO emphasizes that routine health information requires review for quality before meaningful analysis. That matters for China and U.S. comparisons because administrative datasets reflect the systems that create them. Claims data, hospital reports, yearbooks, disease registries, and procurement platforms each record a different slice of reality.
Practical rule
The strongest source is the one closest to the decision. Use the regulator for approval, the payer for payment, the statistical agency for scale, the health authority for system design, the clinical literature for outcomes, and implementation sources for local practice. When a claim crosses several gates, use several source families and say what each one supports.
Research anchors
- CMS guide for medical technology companies for coding, coverage, and payment distinctions.
- FDA Device Advice for U.S. device market pathways.
- WHO Data Quality Assurance for routine health-data quality principles.
- CDC in China for public-health collaboration examples and China program context.